ROCHE COULD LEAPFROG THE INDUSTRY AND BUY THE MOST ADVANCED STEM CELL COMPANY THAT IS EXTREMELY UNDERVALUED AND OVERSOLD
UNRIVALED AND PROVEN trial results demonstrate that Cesca Therapeutics (KOOL) is the most advanced Regenerative Medicine Stem Cell Therapeutics Company.
These results are historical in any field of medicine.
Cesca therapeutics recently announced record shattering clinical trial results from their 17 patient CLI trial:
Before treatment, 100% of “No Option” patients required amputation
12 months after treatment, 82.4% of patients had no amputation
Pain level before treatment on a scale of 0 to 10 was SEVERE at 7.8
Pain level 12 months after treatment was ALMOST NON-EXISTENT at 0.2
6-minute walking distance before treatment was 14.5 meters
6-minute walking distance 12 months after treatment was 157meters
Before treatment, 11 patients had gangrene with or without ulceration
12 months after treatment 0 patients had gangrene or ulceration
NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
THERE WERE NO ADVERSE SIDE EFFECTS.
CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond peers
CESCA shares are trading at less than $2.00 per share.
If CESCA was trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $14.21 per share today.